The Severe Asthmatic: Intubated and Difficult to Ventilate

1999 ◽  
pp. 492-511
Keyword(s):  
Severe Asthmatic

Nebulized salbutamol in the treatment of severe asthmatic attacks in children

1988 ◽  
Vol 28 (2) ◽  
pp. 103-106
Author(s):  
J. de Blic ◽  
P. Rufin ◽  
M.R. Benoist ◽  
D. Renon ◽  
P. Scheinmann ◽  
...  
Keyword(s):  
Severe Asthmatic ◽  
Nebulized Salbutamol

The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients

2014 ◽  
Vol 35 (3) ◽  
pp. 241-249 ◽  
Author(s):  
M. Asghar Pasha ◽  
David Jourd'heuil ◽  
Francis Jourd'heuil ◽  
Lori Mahon ◽  
Francisco Romero ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Airway Inflammation ◽  
Exhaled Nitric Oxide ◽  
Small Airway ◽  
Asthmatic Patients ◽  
Severe Asthmatic

scholarly journals CD9+ Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients

2018 ◽  
Vol 9 ◽  
Author(s):  
Carole Brosseau ◽  
Maxim Durand ◽  
Luc Colas ◽  
Eugénie Durand ◽  
Aurore Foureau ◽  
...  
Keyword(s):  
T Cell ◽  
B Cells ◽  
Cell Apoptosis ◽  
Regulatory B Cells ◽  
Asthmatic Patients ◽  
T Cell Apoptosis ◽  
Severe Asthmatic

A study on symptom improvement and efϑicacy of formoterol plus budesonide in the asthma management in northern parts of Tamil Nadu

2021 ◽  
Vol 12 (1) ◽  
pp. 742-748
Author(s):  
Mani Dhandayuthapani ◽  
Murugesh Shivashankar ◽  
Uma K
Keyword(s):  
Tamil Nadu ◽  
Asthma Management ◽  
Symptom Improvement ◽  
Asthmatic Patients ◽  
Severe Asthmatic ◽  
Number Of Patients ◽  
One Year ◽  
Experienced Symptom

The purpose is to study the asthma symptom improvement and efficacy of formoterol (LABA) and Budesonide (ICS) combination in the asthma management in northern districts of Tamilnadu. It is a multicentric, non-comparative, questionnaire and random sampling study was conducted in 145 mild to severe asthmatic patients. They were in Formoterol plus budesonide combination inhalation drugs available in DPI and pMDI. Among the 145 asthmatic patients, 45 patients, 6 patients and 94 patients were in DPI, nebuliser and pMDI devices respectively. During drug initiation, The Asthmatics were in mild (27%), Moderate (57%) and Severe (16%) stages. After one year of follow-up, the number of patients in the mild is 84%, moderate 14% and severe 2%. Among 45 DPI Asthmatic patients, 29 patients, 15 patients and 1 patient have reported the handling the devices as easy, medium and hard respectively. On the other hand, 94 pMDI asthmatic patients, 38 patients, 48 patients and 8 patients have reported the handling of devices as easy, medium and hard respectively. The treatment resulted in 77 patients as good, 65 as satisfactory and 3 as same. After one year, all the 145 asthmatic patients adhered with the treatment and experienced symptom improvement with 53% patients as good, 45% patients as satisfactory and 2% patients as same. The treatment of formoterol and budesonide combination in the northern districts of Tamilnadu have effectively controlled the asthmatic symptoms and improved the quality of life in asthmatics. Moreover, the patient's adherence to the treatment is good in the northern parts of Tamilnadu.

scholarly journals Distinct profile of inflammatory and remodelling biomarkers in sputum of severe asthmatic patients with or without persistent airway obstruction

2019 ◽  
Vol 12 (11) ◽  
pp. 100078 ◽  
Author(s):  
Silvana Cianchetti ◽  
Cristina Cardini ◽  
Ilaria Puxeddu ◽  
Manuela Latorre ◽  
Maria Laura Bartoli ◽  
...  
Keyword(s):  
Airway Obstruction ◽  
Asthmatic Patients ◽  
Severe Asthmatic

scholarly journals Characteristics and treatment regimens across ERS SHARP severe asthma registries

2019 ◽  
Vol 55 (1) ◽  
pp. 1901163 ◽  
Author(s):  
Job J.M.H. van Bragt ◽  
Ian M. Adcock ◽  
Elisabeth H.D. Bel ◽  
Gert-Jan Braunstahl ◽  
Anneke ten Brinke ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Research Collaboration ◽  
Forced Expiratory Volume ◽  
European Respiratory Society ◽  
Cross Sectional ◽  
Aggregated Data ◽  
Treatment Regimens ◽  
Severe Asthmatic ◽  
Definition Of ◽  
The Uk

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

Sign in / Sign up

Export Citation Format

Share Document